Editorial Staff

Survey Finds Prescription Drug Prices Easy To Access, But Not Always Accurate

/in , , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Wide variation found in price of generics, less for brand-name drugs; consumers must navigate difficult terrain to find lowest price

BOSTON – It’s far easier to get prescription drug price information than to get similar numbers from hospitals or specialty physicians, but the information is not always reliable, according to a new survey published by Pioneer Institute.

Download

Researchers called 44 independent and chain drugstores across Massachusetts and asked for a 30-day supply in a common dosage of five generic and three brand-name drugs.  Callers said they were self-pay and pressed the stores for information about discounts. Massachusetts’ 2012 state law mandating price transparency does not cover retail pharmaceutical sales.

“There were virtually no transfers or dropped calls, no lengthy hold or wait times, and most of our callers were treated with courtesy,” said Barbara Anthony, primary author of “Transparency in Retail Drug Prices: Easy to Obtain but Accuracy May Be Doubtful.”  “However some workers weren’t well informed about the pharmacy’s discount programs and those working in chain stores didn’t refer the callers to drug discount program information on their websites.”

Although most Massachusetts residents have health insurance, between 3 and 4 percent are uninsured at any given time.  Combine that with the rise of high-deductible insurance plans and those who are underinsured, and the result is that many consumers are paying out-of-pocket for all or part of their prescription drugs.

There was significant variation among drugstores in the price of generic drugs, which account for 87 percent of prescriptions filled in the U.S. and typically cost one-third to one-tenth the price of brand-name drugs.

Atorvastatin, a popular generic used to control cholesterol, cost $4 at a pharmacy in Lunenburg and just under $199 at one in Boston.

See full chart in report.

See full chart in report.

There was a much narrower range for the three brand-name drugs about which researchers inquired.

Manufacturers’ coupons and those from companies like GoodRx and OneRx were found to reduce prices significantly for some generic drugs like Atorvastatin and Montelukast, a substitute for the antihistamine Singulair.  But the coupon price was sometimes higher than the price using store discounts for other drugs.

“Finding the lowest price, even among generic drugs, is tough terrain for consumers to navigate,” Anthony said. “Consumers need to consult coupon websites, call stores, shop, compare and try to find the best price at a time they are already in a vulnerable position,” she added.

The value of coupons was also mixed for brand-name drugs.  Using GoodRx reduced the price of Patanol, a popular eye-drop medication, from $335 to $268 at Walgreens, but provided little savings on other drugs.

It was often difficult to get accurate price information over the phone.  Sometimes drugstores couldn’t verify the price of a drug using a discount coupon until the transaction was run through the store’s computer system.  Some major chains will only disclose a “phantom” or average wholesale price for a drug because their computer systems are not able to provide the true price unless the prescription is actually processed.

“Consumers can’t be expected to physically go from pharmacy to pharmacy to get an accurate price,” said Pioneer’s Executive Director Jim Stergios.

The authors make several recommendations:

  • Pharmacy workers should receive better training about communicating prescription drug discount programs and they should refer customers to store websites, where applicable, for more information.
  • Retail drug stores should do more to inform consumers that they accept discount coupons.
  • Store computer systems need to be more consumer friendly and generate accurate prices to consumers who are shopping by phone; the inability to give an accurate price without filling the script impedes transparency and hurts consumers.
  • Consumers should not automatically assume that chain store prices are lower than independent drug store prices, and should know that many independent stores are willing to negotiate to match price. Shopping around can save money even on generic drugs.
  • Consumers should search the internet for discount drug coupons but they should not automatically assume that all coupon prices represent the best possible deal.
  • Prescription drug payers should adopt the level of transparency used by the Medicare program. There, beneficiaries receive an easy-to-read monthly report showing the amount Medicare paid to the pharmacy for each drug, the amount paid by the beneficiary and pharmacy payments from any other payers.

About the Authors     

Barbara Anthony, a lawyer, is a senior fellow in healthcare at Pioneer Institute focusing on healthcare price and quality transparency.  She is also an associate at the Harvard Kennedy School’s Center for Business and Government.  She served as Massachusetts Undersecretary for Consumer Affairs and Business Regulation from 2009 to 2015.

Scott Haller graduated from Northeastern University with a Bachelor’s Degree in Political Science. He started working at Pioneer Institute through the Northeastern’s Co-op Program and continues now as the Lovett C. Peters Fellow in Healthcare. He previously worked at the Office of the Inspector General.

About Pioneer

Pioneer Institute is an independent, non-partisan, privately funded research organization that seeks to improve the quality of life in Massachusetts through civic discourse and intellectually rigorous, data-driven public policy solutions based on free market principles, individual liberty and responsibility, and the ideal of effective, limited and accountable government.

Get Updates On Our Healthcare Cost Transparency Initiative!

Related Research

Pioneer Institute: 340B Hospitals Does Not Necessarily Translate to Charity Care

Review of Becker’s List of Health Systems with Strong Finances…

New Online Tool Tracks MA Hospital Revenue from Commercial Sources

A new online tool from Pioneer Institute shows a gradual increase in non-commercial (public payer) revenue at Massachusetts hospitals and also reveals a strong relationship between the hospitals with the highest commercial revenue and those with the highest relative prices.

Telehealth Progress Slowed in 2023

A new report by Cicero Institute, Pioneer Institute, and Reason Foundation reveals worrying stagnation in state-level telehealth expansion efforts in 2023, with only a few exceptions. Progress made during the pandemic is being lost even as provider shortages worsen, raising concerns about patients’ access to care.

Opinion: Drug patents aren’t a ‘necessary evil.’ They save lives.

Drug patents are one of the most important public policy innovations in all of human history, and a boon to patients awaiting cures. Inventions only come when inventors are rewarded, not punished. Patents are not a “necessary evil.”

Study: High List Prices and Deep Discounts for Prescription Drugs Hurt Poor and Sick Patients

A new Pioneer Institute study illustrates how the current system of drug pricing and discounts leads to patients with challenging diseases being charged huge out-of-pocket sums to keep other premiums low, effectively imposing financial penalties on the sick to protect the healthy and wealthy.

Study: Massachusetts Should Join 45 States and Allow Prescribers to Dispense Medications

A Pioneer Institute study shows that middlemen—commercial pharmacies and pharmacy benefit managers—add substantial costs over wholesale prices. Allowing prescribers to dispense routine drugs would save consumers money without compromising safety.

As COVID-19 Emergencies Ease, Some Progress on Telehealth Rules

A new report from Reason Foundation, Cicero Institute and Pioneer Institute rates every state’s telehealth policy for patient access and ease of providing virtual care. The report highlights telehealth policy best practices for states.

First-of-Its-Kind Interactive Mapping Tool Reveals Extent of For-Profit Entities Benefitting from the 340B Drug Pricing Program

Today, Pioneer Institute released a first-of-its-kind, 50-state mapping tool and database highlighting the troubling way in which hospitals and covered entities leverage unlimited pharmacy contracts under the 340B Drug Pricing Program.

Survey Finds Spotty Compliance Among Hospitals with Federal Price Transparency Law

A 2019 federal law requires hospitals to make prices for 300 shoppable services available online in a “consumer-friendly format,” but a Pioneer Institute survey of 19 hospitals finds that information on discounted cash prices—the price most likely to be charged to consumers paying out of pocket—was unavailable at seven of those hospitals.

Massachusetts Hospitals Pull Back on Charity Care as Revenue from Federal 340B Drug Discount Program Explodes

Over the past decade, the revenue for hospitals generated by the federal 340B drug discount program, initially intended to serve low-income, uninsured populations, has exploded even while a number of important Massachusetts hospitals have reduced the level of charity care they provide, according to a new study published by Pioneer Institute. The Pioneer Institute study, “340B Drug Discounts: An Increasingly Dysfunctional Program,” notes that nationwide, 340B drug sales rose from $9 billion in 2014 to $38 billion in 2020.

The Promise and Challenges of Rare Cancer Treatments

Dr. William Smith, Pioneer Institute's Visiting Fellow in Life Sciences, spoke about the challenges and opportunities for rare cancer treatments, in a video interview produced by Rare Cancers, a patient group based in Australia, for the November 26th CAN Forum. 

Study: Decline in Cardiovascular Health Screenings During COVID-19 Pandemic Poses New Public Health Threat

Pioneer Institute today released a new analysis focused on cardiovascular disease, An “Impending Tsunami” in Mortality from Traditional Diseases?, that examines how the COVID-19 pandemic has created another unrelated public health crisis. The Pioneer analysis examines how a single-minded public health focus on COVID-19, social distancing, and lockdowns drove reductions in screenings, diagnoses, and early treatment for complex conditions such as heart disease.

Pioneer Institute Statement on the Commonwealth’s Discontinuance of the COVID-19 Weekly Public Health Report

Useful information about COVID cases or deaths at individual homes has become less available at a time when cases are increasing again, even among vaccinated residents. Pioneer urges Massachusetts to immediately reinstate the so-called Weekly Report, which contains cases and deaths inside individual nursing homes.

Study: Massachusetts Should Retain Additional Healthcare System Flexibility Granted During Pandemic

Massachusetts’ emergency declaration for COVID-19 ends on June 15, and with it some enhanced flexibility that has been allowed in the healthcare system.  Some of the added flexibility highlighted barriers that make the system more expensive, harder to access and less patient-centered, and the Commonwealth should consider permanently removing these barriers, according to a new study published by Pioneer Institute.

Study Calls for Better Reporting on Impact of COVID-19 in Eldercare Facilities

Over time, the Massachusetts Executive Office of Health and Human Services and Department of Public Health (DPH) have improved reporting about cases and deaths from COVID-19 in state-regulated eldercare facilities, but flaws and omissions remain and should be corrected, according to a new study published by Pioneer Institute.

New Analysis: ICER Framework Ignores Patient Preferences, Innovation & Societal Benefits in Evaluating Cost-Effectiveness of New Cancer Treatments

Pioneer Institute today released a new analysis, The QALY and Cancer Treatments: An Ill-Advised Match, that examines the alarming methodological and contextual shortcomings of the Quality Adjusted Life Years (QALY)-based methodology in evaluating new cancer therapies. The Pioneer Institute analysis reveals five specific problems with ICER’s evaluation of cancer treatments and demonstrates the urgent need to prohibit the use of the QALY amid trends in rapid cancer innovations and personalized medicine.

Study: Massachusetts Should Embrace Direct Healthcare Options

Especially in the COVID era, many are looking to alleviate the increased burden on the healthcare system.  One solution is direct healthcare (DHC), which can provide more patient-centered care at affordable prices and is an effective model to increase access to care for the uninsured, underinsured and those on public programs like Medicaid, according to a new study published by Pioneer Institute.

Survey: Consumers Want Healthcare Price Information, But Few Realize It’s Available

Great strides have been made to increase healthcare price transparency through online cost estimator tools and a state law that requires providers to give out price information. Yet despite the eagerness of consumers to access prices and out-of-pocket costs, many are unaware that such information is available and don’t know how to access it, according to survey results published by Pioneer Institute.